1. (1954) CASE records of the Massachusetts General Hospital Weekly Clinicopathological Exercises: Case 40011. N Engl J Med 250: 26-30.
2. Castleman B, Iverson L, Menendez VP (1956) Localized mediastinal lymphnode hyperplasia resembling thymoma. Cancer 9: 822-30.
3. Gaba AR, Stein RS, Sweet DL, Variakojis D (1978) Multicentric giant lymph node hyperplasia. Am J Clin Pathol 69: 86-90.
4. Frizzera G, Banks PM, Massarelli G, Rosai J (1983) A systemic lymphoproliferative disorder with morphologic features of Castleman’s disease. Pathological findings in 15 patients. Am J Surg Pathol 7: 211-31.
5. Frizzera G, Peterson BA, Bayrd ED, Goldman A (1985) A systemic lymphoproliferative disorder with morphologic features of Castleman’s disease: clinical findings and clinicopathologic correlations in 15 patients. J Clin Oncol 3:1202-16.
6. Weisenburger DD, Nathwani BN, Winberg CD, Rappaport H (1985) Multicentric angiofollicular lymph node hyperplasia: a clinicopathologic study of 16 cases. Hum Pathol 16: 162-72.
7. Oksenhendler E, Boutboul D, Fajgenbaum D (2018) The full spectrum of Castleman disease: 273 patients studied over 20 years. Br J Haematol 180: 206-16.
8. Talat N, Schulte KM (2011) Castleman’s disease: systematic analysis of 416 patients from the literature. Oncologist 16: 1316-24.
9. Soulier J, Grollet L, Oksenhendler E (1995) Kaposi’s sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman’s disease. Blood 86: 1276-80.
10. Boshoff C, Weiss RA (2001) Epidemiology and pathogenesis of Kaposi’s sarcoma-associated herpesvirus. Philos Trans R Soc Lond B Biol Sci 356: 517-34.
11. Martin JN, Ganem DE, Osmond DH, Page-Shafer KA, Macrae D, et al. (1998) Sexual transmission and the natural history of human herpesvirus 8 infection. N Engl J Med 338: 948-54.
12. Fajgenbaum DC, van Rhee F, Nabel CS (2014) HHV-8-negative, idiopathic multicentric Castleman disease: novel insights into biology, pathogenesis, and therapy. Blood 123: 2924-33.
13. Cesarman E, Chang Y, Moore PS, Said JW, Knowles DM (1995) Kaposi’s sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N Engl J Med 332: 1186-91.
14. Porter SR, Di Alberti L, Kumar N (1998) Human herpes virus 8 (Kaposi’s sarcoma herpesvirus). Oral Oncol 34: 5-14.
15. van Rhee F, Stone K, Szmania S, Barlogie B, Singh Z (2010) Castleman disease in the 21st century: an update on diagnosis, assessment, and therapy. Clin Adv Hematol Oncol 8: 486-98.
16. Bower M, Powles T, Williams S (2007) Brief communication: rituximab in HIV-associated multicentric Castleman disease. Ann Intern Med 147: 836-9.
17. Gerard L, Berezne A, Galicier L (2007) Prospective study of rituximab in chemotherapy-dependent human immunodeficiency virus associated multicentric Castleman’s disease: ANRS 117 CastlemaB Trial. J Clin Oncol 25: 3350-6.
18. Corbellino M, Bestetti G, Scalamogna C (2001) Long-term remission of Kaposi sarcoma-associated herpesvirus-related multicentric Castleman disease with anti-CD20 monoclonal antibody therapy. Blood 98: 3473-5.
19. El-Osta HE, Kurzrock R (2011) Castleman’s disease: from basic mechanisms to molecular therapeutics. Oncologist 16: 497-511.
20. Marcelin AG, Aaron L, Mateus C (2003) Rituximab therapy for HIV-associated Castleman disease. Blood 102: 2786-8.
21. Neuville S, Agbalika F, Rabian C, Briere J, Molina JM (2005) Failure of rituximab in human immunodeficiency virus-associated multicentric Castleman disease. Am J Hematol 79: 337-9.
22. Newsom-Davis T, Bower M, Wildfire A (2004) Resolution of AIDS-related Castleman’s disease with anti-CD20 monoclonal antibodies is associated with declining IL-6 and TNF-alpha levels. Leuk Lymphoma 45: 1939-4.